Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells
Immune Network
;
: 99-108, 2016.
Article
Dans Anglais
| WPRIM
| ID: wpr-168218
ABSTRACT
Colorectal cancer is the third leading cancer worldwide. Although incidence and mortality of colorectal cancer are gradually decreasing in the US, patients with metastatic colorectal cancer have poor prognosis with an estimated 5-year survival rate of less than 10%. Over the past decade, advances in combination chemotherapy regimens for colorectal cancer have led to significant improvement in progression-free and overall survival. However, patients with metastatic disease gain little clinical benefit from conventional therapy, which is associated with grade 3~4 toxicity with negative effects on quality of life. In previous clinical studies, cell-based immunotherapy using dendritic cell vaccines and sentinel lymph node T cell therapy showed promising therapeutic results for metastatic colorectal cancer. In our preclinical and previous clinical studies, cytokine-induced killer (CIK) cells treatment for colorectal cancer showed favorable responses without toxicities. Here, we review current treatment options for colorectal cancer and summarize available clinical studies utilizing cell-based immunotherapy. Based on these studies, we recommend the use CIK cell therapy as a promising therapeutic strategy for patients with metastatic colorectal cancer.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pronostic
/
Qualité de vie
/
Cellules dendritiques
/
Vaccins
/
Tumeurs colorectales
/
Incidence
/
Taux de survie
/
Mortalité
/
Association de médicaments
/
Cellules CIK
Type d'étude:
Etude d'incidence
/
Étude pronostique
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Immune Network
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS